Zymeworks Inc.
ZYME Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$28.85
KIRA · Stoqly’s AI analyst, in plain words
- Zymeworks Inc. had $106M of revenue in fiscal 2025, up 38.9% on the year before. Over five years, revenue changed +22.2% a year on average.
- Its operating margin was −87.3%, up 92.3 pts: of every 100 in sales, about −87 is left after running the business.
- Zymeworks Inc. lost $81.1M in fiscal 2025.
- Free cash flow was −$34.5M in fiscal 2025, −32.6% of revenue.
- Zymeworks Inc. returned $41.7M to shareholders in fiscal 2025. The diluted share count fell 0.6%.
Market cap
$2.1B
P/E
—
Revenue
$106M
Net income
−$81.1M
Free cash flow
−$34.5M
Operating margin
−87.3%
Zymeworks Inc. in 30 seconds · fiscal 2025
Are sales growing?
+38.9%
Yes. Sales grew 38.9% last year.
Does it make a profit?
−76.6%
No. It lost money last year.
Does profit turn into cash?
−32.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Zymeworks Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Zymeworks Inc.
- CIK
- 0001937653
Zymeworks Inc. · ZYME
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $26.7M | $412M | $76.0M | $76.3M | $106M |
| Revenue growth | −31.5% | 1,446.0% | −81.6% | 0.4% | 38.9% |
| Operating margin | −808.2% | 31.6% | −181.6% | −179.7% | −87.3% |
| Net income | −$212M | $124M | −$119M | −$123M | −$81.1M |
| Net margin | −794.0% | 30.1% | −156.1% | −160.8% | −76.6% |
| Diluted EPS | −$4.61 | $1.90 | −$1.72 | −$1.62 | −$1.08 |
| Cash | |||||
| Cash from operations | −$192M | $144M | −$118M | −$110M | −$33.0M |
| Capital expenditure | $12.4M | $8.2M | $2.5M | $2.0M | $1.5M |
| Free cash flow | −$205M | $136M | −$121M | −$112M | −$34.5M |
| FCF margin | −767.8% | 33.0% | −158.9% | −146.8% | −32.6% |
| Share buybacks | — | $0.0M | $0.0M | $30.1M | $41.7M |
| Share count change | 3.5% | 25.2% | 5.5% | 10.2% | −0.6% |
| Debt and strength | |||||
| Cash and short-term investments | $253M | $492M | $374M | $66.1M | $41.2M |
| Shareholders' equity | $249M | $493M | $465M | $339M | $269M |
| Current ratio | 4.0x | 5.7x | 7.4x | 3.4x | 5.9x |
| Returns and quality | |||||
| Return on equity | −64.3% | 33.5% | −24.8% | −30.5% | −26.7% |
| Return on tangible equity | −90.8% | 26.3% | −26.7% | −38.1% | −31.8% |
| Piotroski F-score | — | 6 | 2 | 2 | 5 |
| Altman Z'' | −3.9 | 6.4 | 2.8 | −2.0 | −3.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$5.0M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Zymeworks Inc. · ZYME
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $28.85 a share, the company is worth $2.1B.
Source: SEC EDGAR XBRL filings (CIK 0001937653). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.